About the journal

Cobiss

Srpski arhiv za celokupno lekarstvo 2015 Volume 143, Issue 1-2, Pages: 108-115
https://doi.org/10.2298/SARH1502108T
Full text ( 322 KB)
Cited by


Contemporary nuclear medicine diagnostics of neuroendocrine tumors

Todorović-Tirnanić Mila (School of Medicine, Belgrade + Clinical Center of Serbia, Center for Nuclear Medicine, Belgrade)
Artiko Vera ORCID iD icon (School of Medicine, Belgrade + Clinical Center of Serbia, Center for Nuclear Medicine, Belgrade)
Pavlović Smiljana (School of Medicine, Belgrade + Clinical Center of Serbia, Center for Nuclear Medicine, Belgrade)
Šobić-Šaranović Dragana ORCID iD icon (School of Medicine, Belgrade + Clinical Center of Serbia, Center for Nuclear Medicine, Belgrade)
Obradović Vladimir (School of Medicine, Belgrade + Clinical Center of Serbia, Center for Nuclear Medicine, Belgrade)

The new positron emission tomography (PET/CT) methods for neuroendocrine tumors detection are presented and compared with classic, conventional methods. Conventional methods use a gamma scintillation camera for patients with neuroendocrine tumor imaging, after intravenous injection of one of the following radiopharmaceuticals: 1) somatostatin analogues labeled with indium-111 (111In-pentetreotide) or technetium-99m (99mTc-EDDA/HYNIC-TOC); 2) noradrenaline analogue labeled with iodine-131 or -123 (131I/123I-MIBG); or 3) 99mTc(V)-DMSA. Contemporary methods use PET/CT equipment for patients with neuroendocrine tumor imaging, after intravenous injection of pharmaceuticals labeled with positron emitters [fluorine-18 (18F), galium-68 (68Ga), or carbon-11 (11C)]: 1) glucose analogue (18FDG); 2) somatostatin analogue (68Ga-DOTATOC/68Ga-DOTATATE/68Ga-DOTANOC); 3) aminoacid precursors of bioamines: [a) dopamine precursor 18F-DOPA (6-18F-dihydroxyphenylalanine), b) serotonin precursor 11C-5HTP (11C-5-hydroxytryptophan)]; or 4) dopamine analogue 18F-DA (6-18F-fluorodopamine). Conventional and contemporary (PET/ CT) somatostatin receptor detection showed identical high specificity (92%), but conventional had very low sensitivity (52%) compared to PET/CT (97%). It means that almost every second neuroendocrine tumor detected by contemporary method cannot be discovered using conventional (classic) method. In metastatic pheochromocytoma detection contemporary (PET/ CT) methods (18F-DOPA and 18F-DA) have higher sensitivity than conventional (131I/123I-MIBG). In medullary thyroid carcinoma diagnostics contemporary method (18F-DOPA) is more sensitive than conventional 99mTc(V)-DMSA method, and is similar to 18FDG, computed tomography and magnetic resonance. In carcinoid detection contemporary method (18F-DOPA) shows similar results with contemporary somatostatin receptor detection, while for gastroenteropancreatic neuroendocrine tumors it is worse. To conclude, contemporary (PET/CT) methods for somatostatin receptor detection (68Ga-DOTATOC/-NOC/-TATE) in neuroendocrine tumors are much more sensitive (almost twice) and more accurate than conventional. Therefore the classical methods should be urgently replaced by contemporary methods.

Keywords: neuroendocrine tumors, 68Ga-DOTATOC, 18F-DOPA, 18FDG, 6-18F-fluorodopamine, 11C-5-hydroxytryptophan